@igcpharma.bsky.social expands #IGC_AD1 Phase 2 #clinicaltrials to Hamilton Health Sciences in Canada, strengthening Alzheimer’s agitation research and accelerating patient enrollment.
clinicaltrials.gov/study/NCT055...

#IGCPharma #Alzheimers #Neurodegeneration #AlzheimersResearch